# Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease

Study · id `cardio:ct-nct03499639` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03499639](<https://clinicaltrials.gov/study/NCT03499639>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03499639

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT03499639. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2018-08-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT03499639, source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)
- Started: 2018-05-01 (actual) (ClinicalTrials.gov record NCT03499639, source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)
- Primary completion: 2018-08-01 (actual) (ClinicalTrials.gov record NCT03499639, source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)
- Completion: 2018-09-30 (actual) (ClinicalTrials.gov record NCT03499639, source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT03499639, source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03499639-2020-01-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
- Condition: End-stage Renal Disease
- Condition: HCV Coinfection
- Intervention (Drug): Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
- Lead sponsor: Assiut University
- Lead sponsor class: OTHER
- Collaborator: Sohag University
- Collaborator class: OTHER
- Collaborator: South Valley University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Assiut University (`cardio:org-assiut-university`)
- Registry lists this organization as a collaborator: Sohag University (`cardio:org-sohag-university`)

## Provenance

Content hash: 22499048e5395b47af94661ba4d2b5b76c106377c57203d33aaa8dc0678e7e5d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
